Medical Health & Life Science Research News

Learn details of the gastrointestinal stromal tumor (GIST) - pipeline review, H1 2018

Medical Market Research

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract.

If you are want to study the Gastrointestinal Stromal Tumor (GIST) or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs. 

Get Access to Sample PDF @:…l-stromal-tumor-6 Make an Inquiry about this news

Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Key Players included in the research study are AB Science SA, Ariad Pharmaceuticals Inc, Arog Pharmaceuticals Inc, ArQule Inc, Array BioPharma Inc, Ascentage Pharma Group Corp Ltd, Bayer AG, Blueprint Medicines Corp, Boston Biomedical Inc, Calithera Biosciences Inc, Celldex Therapeutics Inc, Chipscreen Biosciences Ltd, Daiichi Sankyo Co Ltd, Deciphera Pharmaceuticals LLC, Eli Lilly and Co, Exelixis Inc, F. Hoffmann-La Roche Ltd, Hanmi Pharmaceuticals Co Ltd, Horizon Pharma Plc, Immunicum AB, Jiangsu Hengrui Medicine Co Ltd, Loxo Oncology Inc, Merck & Co Inc, Merck KGaA, Natco Pharma Ltd, Nerviano Medical Sciences Srl, Novartis AG, Omeros Corp, Pfizer Inc, Pharma Mar SA, Plexxikon Inc, Rhizen Pharmaceuticals SA, Soricimed Biopharma Inc, Taiho Pharmaceutical Co Ltd & Xencor Inc. 

Make inquiry @…l-stromal-tumor-6 Make an Inquiry about this news 

The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. 

Gastrointestinal Stromal Tumor (GIST) pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision making capabilities and helps to create effective marketing strategies to gain competitive advantage in health care and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real time basis. 

Access this research report @…mp;report=1171465 Make an Inquiry about this news 

Extracts of Chapters from Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018 
Chapter 1 , to describe the definition , overview and Therapeutics Development of Gastrointestinal Stromal Tumor (GIST). 
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes. 
Chapter3, Therapeutics Assessment of Gastrointestinal Stromal Tumor (GIST) by Target, Mechanism of Action, Route of Administration and by Molecule Type. 
Chapter4, to display company profile involved in Therapeutics Development. 
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Gastrointestinal Stromal Tumor (GIST). 
Chapter 6,7, to describe Gastrointestinal Stromal Tumor (GIST) Appendix, Methodology ,Coverage ,Secondary Research ,Primary Research ,Expert Panel Validation and Contact Us. 

Objective of this study 

- To provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (GIST). 
- To reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 
- The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 
- The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (GIST) therapeutics and enlists all their major and minor projects. 
- The pipeline guide evaluates Gastrointestinal Stromal Tumor (GIST) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. 
- The guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (GIST) 

Reasons to access 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. 
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. 
- Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (GIST). 
- Classify potential new clients or partners in the target demographic. 
- Develop tactical initiatives by understanding the focus areas of leading companies. 
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. 
- Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (GIST) pipeline depth and focus of Indication therapeutics. 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. 
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. 

Read Detailed Index of full Research Study at @…l-stromal-tumor-6 Make an Inquiry about this news 

News From

HTF Market Intelligence ConsultingHTF Market Intelligence...
Category: Market Research Publishers and RetailersCompany about: HTF Market Report is wholly owned brand of HTF market Intelligence Consulting Private Limited which provides next-generation service for organizations with a deep focus on market intelligence, data analytics, and social intelligence, all uniquely delivered under one roof by skilled professionals. By combining and analyzing acquire lucid and most relevant data which would help in better decision-making. We provide your requirements with speed and cost benefit across the world, we are able to achi ...
This email address is being protected from spambots. You need JavaScript enabled to view it.

For more information:

Make an Inquiry about this report HERE!